Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Lemberg, Kathryn M.; Zhao, Liang; Wu, Ying; Veeravalli, Vijayabhaskar; Alt, Jesse; Aguilar, Joanna Marie H.; Dash, Ranjeet P.; Lam, Jenny; Tenora, Lukáš; Rodriguez, Chabely; Nedelcovych, Michael T.; Brayton, Cory; Majer, Pavel; Blakeley, Jaishri O.; Rais, Rana; Slusher, Barbara S.

doi:10.1158/1535-7163.22506892.v1

15357163mct190319-sup-219616_2_supp_5785094_py13k1.pdf (898.23 kB)

Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

journal contribution

posted on 2023-04-03, 15:28 authored by Kathryn M. Lemberg, Liang Zhao, Ying Wu, Vijayabhaskar Veeravalli, Jesse Alt, Joanna Marie H. Aguilar, Ranjeet P. Dash, Jenny Lam, Lukáš Tenora, Chabely Rodriguez, Michael T. Nedelcovych, Cory Brayton, Pavel Majer, Jaishri O. Blakeley, Rana Rais, Barbara S. Slusher

Supplemental Figure 4: Weight changes in non-tumored NPcis mice over one month of daily JHU395 dosing.

Funding

NIH

Ministry of Education

History

ARTICLE ABSTRACT

The carbon and nitrogen components of glutamine are used for multiple biosynthetic processes by tumors. Glutamine metabolism and the therapeutic potential of glutamine antagonists (GA), however, are incompletely understood in malignant peripheral nerve sheath tumor (MPNST), an aggressive soft tissue sarcoma observed in patients with neurofibromatosis type I. We investigated glutamine dependence of MPNST using JHU395, a novel orally bioavailable GA prodrug designed to circulate inert in plasma, but permeate and release active GA within target tissues. Human MPNST cells, compared with Schwann cells derived from healthy peripheral nerve, were selectively susceptible to both glutamine deprivation and GA dose-dependent growth inhibition. In vivo, orally administered JHU395 delivered active GA to tumors with over 2-fold higher tumor-to-plasma exposure, and significantly inhibited tumor growth in a murine flank MPNST model without observed toxicity. Global metabolomics studies and stable isotope–labeled flux analyses in tumors identified multiple glutamine-dependent metabolites affected, including prominent effects on purine synthesis. These data demonstrate that glutamine antagonism is a potential antitumor strategy for MPNST.

Usage metrics

Keywords

Pediatric Cancers Pharmacology Pharmacokinetics and pharmacodynamics Preclinical toxicology Sarcomas Soft-tissue sarcoma Small Molecule Agents

Licence

CC BY

Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Funding

NIH

Ministry of Education

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports